Neuroscience
Steering Committee

The Biomarkers Consortium’s Cancer, Inflammation and Immunity, Metabolic Disorders and Neuroscience Steering Committees are responsible for identifying and moving forward promising pre-competitive biomarkers projects for implementation by the Biomarkers Consortium, as well as overseeing each individual project under its purview. The members of each Steering Committee represent a variety of sectors, including academia, government, industry and not-for-profit/advocacy organizations, and are led by two co-chairs representing two of the following three sectors: academia, government or industry.

Linda Brady, Ph.D., NIH/NIMH (Co-Chair)

Hartmuth Kolb, Ph.D., Janssen (Co-Chair)

William Potter, M.D., Ph.D., NIH/NIMH (Co-Chair Emeritus)

Alexandre Akoulitchev, M.A., Ph.D., Oxford Biodynamics

Lammert Albers, Global Alzheimer’s Platform Foundation

Anthony Bannon, Ph.D., AbbVie

Daniel Barboriak, M.D., Radiological Society of North America

Wade Berrettini, M.D., Ph.D., UPenn

Nicole Bjorklund, Ph.D., Alzheimer’s Drug Discovery Foundation

Jonathan Blackburn, Ph.D., MASSAf, Sengenics

Mathias Blom, M.D., Ph.D., Rhino Health

Silvana Borges, M.D., FDA

Jonathon Brzezinski, Ph.D., Clarivate

Diane Bovenkamp, Ph.D., BrightFocus Foundation

Danielle Boyce, The Robert Packard Center for ALS Research at Johns Hopkins

Brian Campbell, Ph.D., Sage Therapeutics

Marc Cantillon, M.D., Sunbird Bio

Maria Carrillo, Ph.D., Alzheimer’s Association

Susan Catalano, Ph.D., Cognition Therapeutics

Caroline Cohen, Ph.D., Sanofi

Susan Croll, Ph.D., Regeneron

Diana David, Ph.D., Danaher

Francesca De Simone, Ph.D., Fujirebio

Ken Duckworth, M.D., NAMI

John Dwyer, J.D., Global Alzheimer’s Platform Foundation

Rebecca Edelmayer, Ph.D., Alzheimer’s Association

Rianne Esquivel, Ph.D., Fujirebio

Yuehan Feng, Ph.D., Biognosys

Howard Fillit, M.D., Alzheimer’s Drug Discovery Foundation

Thomas Finn, Ph.D., FDA

Bernard Fischer, M.D., FDA/CDER

Just Genius, M.D., UCB

Danielle Graham, Ph.D., Biogen

Ida Grudenberg, Ph.D., Olink Proteomics

Glenn Harris, Ph.D., Rainwater Charitable Foundation

Lyn Jakeman, Ph.D., NINDS

Katherine Jung, Ph.D., NIH/NIAAA

Morten Karsdal, Ph.D., M.Sc., mMBA, Nordic Bioscience A/S

Hartmuth Kolb, Ph.D., Enigma Biomedical Group

Walter J. Koroshetz, M.D., NIH/NINDS

Frank Lebeda, Ph.D., US Military

Kristina Malzbender, Gates Ventures

Eliezer Masliah, Ph.D., NIH/NIA

Bradley Miller, M.D., Ph.D., Eli Lilly

David Millis, M.D., M.B.A., Ph.D., FDA/CDER

Larry Mimms, P.D., Schizophrenia & Psychosis Action Alliance

Laura Mitic, Ph.D., The Bluefield Project to Cure FTD

Jose Luis Molinuevo, M.D., Ph.D., Barcelona Beta Brain Research Center

Mike Montalto, Ph.D., PathAI

Prodromos Parasoglou, Ph.D., Regeneron

Lovingly Park, Ph.D., Alector

Rodney Pearlman, Ph.D., The Bluefield Project to Cure FTD

Mary Ann Pelleymounter, Ph.D., NIH/NINDS

Chris Petropoulos, LabCorp

Niels Plath, Ph.D., Lundbeck

Josh Porter, Olink Proteomics

Kurt Rasmussen, Ph.D., NIH/NIDA

Sounder Regunathan, Ph.D., NIH/NIAAA

Cristina Sampaio, M.D., Ph.D., CHDI Foundation

Steve Sands, Ph.D., Amgen

Bob Schafer, Ph.D., Lumos Labs

Nina Schor, Ph.D., NIH/NINDS

Howard Schulman, Ph.D., Allosteros Therapeutics

Lamya Shihabuddin, Ph.D., Sanofi

Daniel Smith, Ph.D., Alkermes

Sean Smith, Ph.D., Merck

Gad Soffer, General Metabolics

Arie Struyk, M.D., Ph.D., Merck

Joyce Suhy, Ph.D., BioClinica

Nadine Tatton, Ph.D., The Association for Frontotemporal Degeneration

Johannes Tauscher, M.D., Takeda

Angela Taylor, Lewy Body Dementia Association

Keith Taylor, Ph.D., Lewy Body Dementia Association

Chris Turck, Ph.D., Max Planck Institute of Psychiatry

Eugeen Vanmechelen, Ph.D., ADx Neurosciences

Sean Walsh, Ph.D., Radiomics

Chris Weber, Ph.D., Alzheimer’s Association

Joel Wommack, Ph.D., SomaLogic

Stephen Wood, Amgen

Kevin Yarasheski, Ph.D., C2N Diagnositcs

Henrik Zetterberg, M.D., Ph.D., University of Gothenburg